Authors
Latest:
Dr. McKinney on the Potential for Curative-Intent Therapies in MCLMatthew S. McKinney, MD, discusses the potential for curative-intent therapies in mantle cell lymphoma.
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume DelineationThe ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Latest:
Key Takeaways: Advancements and Challenges in Kidney Cancer TreatmentLeading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Latest:
What Oncology and Hematology Fellows Can Do to Reduce Their Loan DebtWhile debt from medical school loans is inevitable for most oncology and hematology fellows, there are strategies they can consider to lessen that burden.
Latest:
The Biology of BurnoutBurnout is a recurring problem for overworked oncologists and hematologists. This article includes ideas to keep you healthy, engaged, and empathic.
Latest:
Dr. Yurgelun on Educating Patients on Genetic Testing for CRCMatthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer, as well as some of the common risk factors for the disease.
Latest:
Dr. Htut on Immunotherapy in Multiple MyelomaMaung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.
Latest:
Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast CancerMaura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.
Latest:
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung CancerMaurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+ non-small cell lung cancer.
Latest:
Time Required to Address Scientific Questions Generates an Information DilemmaOne of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.
Latest:
Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual PatientsSerious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.
Latest:
Dr Markman on the Role of PARP Inhibitors in Ovarian CancerMaurie Markman, MD, discusses the unique role of PARP inhibitors in the treatment of patients with ovarian cancer.
Latest:
Dr. Topp on the Safety Profile of Glofitamab Plus R-CHOP in DLBCLMax S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.
Latest:
Wicha Sees Potential for Significant Expansion of Anti-HER2 TherapyMax S. Wicha, MD, is an internationally renowned research expert in the field of breast oncology. His lab was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.
Latest:
The New Medical Oncology/Palliative Medicine Fellowship TrackMedical oncology is a complex field, rich in basic science, mechanism of actions, and cutting-edge clinical investigation but also physical, emotional, social, and existential distress for the patient.
Latest:
Dr. Diehn on Next Steps With Liquid Biopsies in Lung CancerMaximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.
Latest:
Dr. Jochelson on the Limitations of Mammography and Ultrasound in Screening for Breast CancerMaxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.
Latest:
Preventing Chemotherapy-Induced Cardiomyopathy: Can We? Should We?Anthracyclines widely used for a variety of malignancies cause cardiotoxic effects that manifest as cardiomyopathy. Maya E. Guglin, MD, PhD, discusses supportive therapy for these patients.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Dr Shadman on the Impact of Early Dose Reduction on Real-World Outcomes With Ibrutinib in CLL/SLLMazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.
Latest:
A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLLKey opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.
Latest:
Saving Time, Money, and Trouble With an Inventory Management UpgradeChanges in cancer care, regulations, and reimbursement create more pressure on practices than ever before to improve care, reduce costs, and remain viable in an atmosphere of mergers and acquisitions.
